Animal study (ferret) · PMID 39043357

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets — VialBase Research

Ipamorelin (1-3 mg/kg IP) inhibited cisplatin-induced weight loss in ferrets

Last updated · 2024 · Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA · Physiology & Behavior
Key findings
  • Ipamorelin (1-3 mg/kg IP) inhibited cisplatin-induced weight loss in ferrets
  • Anamorelin exhibited both anti-emetic and weight-preserving effects; ipamorelin only weight-preserving
  • Both compounds act through GHS-R1a (ghrelin receptor) but with differing pharmacological profiles
  • Ipamorelin did not significantly inhibit emesis unlike anamorelin
  • Supports appetite-stimulating role of GHS-R1a activation by ipamorelin

Summary

Investigation of whether ghrelin mimetics (anamorelin and ipamorelin) can alleviate weight loss and feeding inhibition during cisplatin-induced emesis in ferrets. Ferrets received anamorelin (1-3 mg/kg) or ipamorelin (1-3 mg/kg) intraperitoneally. Both compounds inhibited weight loss, but only anamorelin exhibited direct anti-emetic effects. The study also compared their ability to inhibit electrical field stimulation (EFS)-induced contractions of isolated ferret ileum.

Key Findings

  • Ipamorelin prevented cisplatin-induced weight loss at 1-3 mg/kg IP doses
  • Unlike anamorelin, ipamorelin did not exhibit anti-emetic effects — suggesting different downstream signaling despite shared GHS-R1a agonism
  • Anamorelin inhibited emesis via a central mechanism
  • The weight-preserving effect of ipamorelin supports its appetite-stimulating properties
  • Differential pharmacological profiles despite acting on the same receptor

Relevance to Ipamorelin

This is the most recent dedicated ipamorelin study in PubMed. It confirms ipamorelin’s GHS-R1a-mediated appetite-stimulating and weight-preserving properties while revealing that it lacks the anti-emetic effects of anamorelin. This pharmacological distinction is important for understanding ipamorelin’s selectivity profile — it stimulates GH release and appetite but does not engage all ghrelin receptor downstream pathways equally.

Citation

Lu Z, et al. Physiol Behav. 2024;284:114644. PMID: 39043357

See Also